pH Pharma and Immunome Enter into Collaboration and License Agreement to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates in Oncology
News
Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression
Findings show that REL-1017 has rapid onset and sustained antidepressant efficacy with statistically significant differences compared to placebo on all efficacy measures
Mebias Discovery Raises $3.5 Million to Expand Pipeline Using a Novel, Cell Signaling-Pathway Selective GPCR Drug Discovery Platform
Developing Programs to Focus on GI and Inflammation Therapies with Reduced, or No, Side Effects
VenatoRx Pharmaceuticals Names Joseph C. Larsen, Ph.D. Vice President, Strategic Portfolio Development
VenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections
– Demonstrated potent activity against carbapenem-resistant Enterobacteriaceae and carbapenem-resistant Pseudomonas aeruginosa
– VNRX-5133 may provide a therapeutic option for these emerging pathogens, which are classified as urgent public health threats by the Centers for Disease Control and Prevention
Bainbridge Health Partners with Tabula Rasa HealthCare’s subsidiary DoseMe To Expand Medication Management Capabilities to Health Systems(s)
VenatoRx Pharmaceuticals Expands Development Team as It Advances Its Antibacterial and Antiviral Portfolio
Key Hires in Quality Assurance, Medical Sciences and Regulatory Affairs